Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/17085381221135271 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial.
Lancet Neurol
January 2025
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Department of Clinical Trial Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Electronic address:
Background: Intra-arterial prourokinase has been shown to be a promising thrombolytic agent in patients with acute ischaemic stroke. Given the global shortage of thrombolytics, we aimed to assess the non-inferiority of intravenous recombinant human prourokinase compared with alteplase in patients with acute ischaemic stroke who were ineligible for or who refused endovascular thrombectomy.
Methods: PROST-2 was a phase 3, open-label, non-inferiority, randomised controlled trial conducted at 61 hospitals in China.
Protamine Dosing for Heparin Reversal after Cardiopulmonary Bypass: A Double-blinded Prospective Randomized Control Trial Comparing Two Strategies.
Anesthesiology
January 2025
Department of Anesthesiology, Perioperative Medicine, and Pain Management, University of Miami, Miller School of Medicine, Miami, Florida.
Article Synopsis
- Drug shortages, especially for medications like protamine, challenge clinical practices; conventional dosing methods may lead to excess usage and risk of harm.* -
- In a study involving cardiac surgery patients, researchers compared a fixed 250 mg dose of protamine to a ratio-based dosing method (1 mg for every 100 U heparin) for effectiveness in reversing heparin's effects.* -
- Results showed no significant difference in the effectiveness of both dosing methods, but the fixed dose resulted in significantly lower total protamine usage without increasing postoperative bleeding.*
A Retrospective Analysis of the Underlying Health Status of Patients Treated for Stroke in the Emergency Department of a Community Hospital Situated in a Health Professional Shortage Area.
Cureus
August 2024
Crouse Neuroscience Institute, Crouse Health at Crouse Hospital, Crouse Medical Practice, PLLC, Syracuse, USA.
Background Hypertension, diabetes, and hyperlipidemia are known contributors to the incidence of stroke. These and other risk factors such as smoking can be managed with effective primary care, but living in a medically underserved area and racial background can limit access, thereby deleteriously affecting underlying medical conditions and disproportionately contributing to negative stroke outcomes. Our goal is to learn about the on-admission health of 1,731 stroke patients who presented to the Crouse Hospital emergency department (ED) between January 2019 and January 2021 to better understand the circumstances affecting these patients.
View Article and Find Full Text PDFPharmacokinetics and pharmacodynamics of low doses of recombinant tissue plasminogen activator to establish a model for biosimilarity comparisons.
Res Pract Thromb Haemost
August 2024
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Background: Recombinant tissue plasminogen activator (rt-PA) is a thrombolytic agent and essential in emergency medical care. Given recent supply shortages, the availability of biosimilar products is an urgent medical need. However, biosimilarity trials are difficult to perform in critically ill patients.
View Article and Find Full Text PDFNear-Infrared II Agent with Excellent Overall Performance for Imaging-Guided Photothermal Thrombolysis.
ACS Nano
September 2024
Center for Aggregation-Induced Emission, AIE Institute, South China University of Technology, Guangzhou 510640, China.
Near-infrared II (NIR-II) imaging and photothermal therapy hold tremendous potential in precision diagnosis and treatment within biological organisms. However, a significant challenge is the shortage of NIR-II fluorescent probes with both high photothermal conversion coefficient (PCE) and fluorescence quantum yield (Φ). Herein, we address this issue by integrating a large conjugated electron-withdrawing core, multiple rotors, and multiple alkyl chains into a molecule to successfully generate a NIR-II agent 4THTPB with excellent PCE (87.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!